Association of FGF23 with Incident Sepsis in Community-Dwelling Adults: A Cohort Study

Abstract

BackgroundFibroblast growth factor 23 (FGF23) is a hormone that regulates vitamin D activity. Higher circulating FGF23 concentrations have been associated with an increased risk of infection-related hospitalization, but the association of FGF23 with risk of sepsis remains unclear.MethodsWe examined the association of FGF23 with incident sepsis events in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a national longitudinal cohort of black and white adults ≥45 years of age. Using a case-cohort design, we measured baseline FGF23 in 703 sepsis cases and in 991 participants randomly selected from the REGARDS cohort. We defined sepsis as the presence of a serious infection plus two or more Systemic Inflammatory Response Syndrome criteria. We identified first sepsis hospitalizations during 2003–2012 by adjudicated medical record review. Cox proportional hazards models were used to examine associations of FGF23 with incident sepsis, adjusting for age, sex, race, income, education, smoking, body mass index, physical activity, chronic pulmonary disease, eGFR, urine albumin-creatinine ratio, and high-sensitivity C-reactive protein. We also examined whether associations differed by age, race, sex, and CKD by testing interaction terms.ResultsHigher FG23 concentrations were associated with greater risk of sepsis (hazard ratio [HR] per doubling of FGF23, 1.37; 95% CI, 1.22 to 1.54) in models adjusted for sociodemographic and clinical variables. After further adjusting for eGFR, urine albumin-creatinine ratio, and high-sensitivity C-reactive protein, the association was attenuated and no longer statistically significant (HR per doubling, 1.01; 95% CI, 0.85 to 1.21). The results did not statistically differ by strata of age, sex, race, or CKD.ConclusionsIn community-dwelling adults, higher FGF23 concentrations were not independently associated with higher risk of sepsis.

Reproducibility in Research: The Role of Kidney360

“…Among hospitalized patients receiving RAAS blockers, the risk of AKI is not higher in those receiving concurrent NSAIDs versus opioids for analgesia 49 Prior use of RAAS inhibitors is not associated with adverse outcomes in patients hospitalized with COVID-19 50 Higher FGF23 levels in outpatients are not associated with a higher risk of sepsis 51 Short-term rifaximin does not lower gut-derived cardiovascular toxins and inflammatory cytokines in patients with chronic kidney disease 52 Autosomal dominant polycystic disease does not increase the risk of starting dialysis after COVID-19 53 Pkd1 mutation does not impair lipid metabolism 54 Proactive intravenous iron administration does not increase the risk of stroke in hemodialysis patients 55 Bleeding after a kidney biopsy is not more likely in obese patients 56 RAAS, renin-angiotensin-aldosterone system; NSAID, nonsteroidal anti-inflammatory drug; COVID-19, coronavirus disease 2019; FGF23, fibroblast growth factor 23.…”